⚡ Store in Development — product images, descriptions, and pricing are placeholders. Final catalog launches soon.

SaltyFuelShop

Does Alzheimer’s Start in the Nasal Cavity? What the Scent and Memory Research Shows

Alzheimer’s nasal cavity connection shown in a cutaway head diagram

Alzheimer’s may start in the nasal cavity, according to Neal K. Shaw, a caregiving researcher with Johns HopKins University and the National Institute of Health.

By Neal K. Shaw, caregiving researcher with Johns Hopkins University and the National Institute of Health

Editorial note: This report checks the small trial’s measured outcome, the meaning of its 226% comparison, the evidence connecting smell loss with health risks, and the limits of claims about Alzheimer’s disease. The named sources are Neal K. Shaw, the UC Irvine trial described in the source material, and the linked scientific studies.

What Did the Nighttime Scent Trial Find?

The UC Irvine clinical trial enrolled older adults who received natural scents from a bedroom diffuser for two hours each night. According to Need To Know News, after six months, the scent group recorded a 226% improvement on standard memory tests compared with controls. The researchers also reported stronger neural pathways, according to the source material.

The 226% figure describes a comparison between measured outcomes in the trial groups. The supplied research does not identify the full paper methods, participant count, statistical results or underlying memory-test scores.

The study tested a nightly exposure and measured memory performance.

Does This Prove Alzheimer’s Starts in the Nose?

No. The cribriform plate, bare olfactory nerve endings and possible nasal routes for inhaled material give researchers reasons to investigate the nasal cavity, but the evidence does not establish it as the starting point of Alzheimer’s disease.

The cribriform plate forms part of the roof of the nasal cavity and contains small openings through which bare olfactory nerve endings extend. These endings lack a blood-brain barrier at that location, which creates a plausible route for inhaled material to reach tissue connected with brain circuits. Research discussed in the source material examined bacteria and vehicle soot as possible examples of inhaled material that may enter brain tissue through nasal pathways.

A 2025 longitudinal study in Frontiers in Aging Neuroscience analyzed 364,945 UK Biobank participants. Chronic rhinosinusitis was associated with an increased risk of Alzheimer’s disease, with a hazard ratio of 1.33 and a 95% confidence interval of 1.04 to 1.71. It was not associated with all-cause dementia, which had a hazard ratio of 1.04 and a 95% confidence interval of 0.86 to 1.26, or vascular dementia, which had a hazard ratio of 0.65 and a 95% confidence interval of 0.40 to 1.07.

The researchers also found that a very small part of the relationship was mediated by the systemic immune-inflammation index, which accounted for 0.0042 of the association.

What Does Smell Loss Tell Older Adults?

Smell loss can provide a reason for a medical discussion, although it cannot diagnose Alzheimer’s disease by itself.

That finding concerns risk prediction. A decline in smell can have causes other than Alzheimer’s disease, so it should not be treated as a diagnosis. The practical response is to discuss the change with a clinician rather than assume its cause.

The olfactory system also has direct anatomical connections with memory networks. Olfactory sensory neurons send projections to the olfactory bulb and then to primary olfactory cortices, including parts of the entorhinal cortex.

The researchers noted that cerebrospinal-fluid lymphatic drainage crosses the cribriform plate, so the olfactory epithelium may provide an accessible place to monitor neuroinflammatory processes. Their proposal concerns research into biomarkers and disease biology.

What Does the Evidence Support?

Reader Question Evidence Type What It Supports What It Does Not Support
Does this prove Alzheimer’s starts in the nose? Anatomical research, animal and pollution studies, and observational cohort research A plausible nasal route for studying inhaled material and inflammation Clinical prevention methods
Does smelling at night restore lost memory? UC Irvine clinical trial A 226% between-group difference in memory-test performance after six months An Alzheimer’s treatment
Can smell loss identify Alzheimer’s? Longitudinal mortality research and olfactory research A possible early warning sign that merits clinical discussion A diagnosis based on smell loss alone
Does nasal research lead to a biopsy or treatment? Human tissue study and proposed biomarker methods A possible way to sample olfactory tissue during research A treatment for Alzheimer’s disease

Established Treatments and This Separate Nasal Research

The scent trial and nasal-biopsy research should be considered separately from trials of established Alzheimer’s medicines. One exception is that the UC Irvine trial tested scent exposure, not either of the antibodies discussed below.

A 2026 Journal of Prevention of Alzheimer’s Disease report examined three-year results from the donanemab long-term extension of TRAILBLAZER-ALZ 2. Participants who received donanemab during the initial 76-week placebo-controlled period had a three-year CDR-Sum of Boxes difference of -1.2 points versus a weighted Alzheimer’s Disease Neuroimaging Initiative control. Their 95% confidence interval was -1.7 to -0.7. The report found no new safety signals compared with the established donanemab safety profile.

A separate 2025 Alzheimer’s & Dementia report described 36-month results from the open-label extension of the phase 3 Clarity AD study of lecanemab. Participants who entered the extension received open-label treatment. The authors reported continued benefits through 36 months across clinical and health-related quality-of-life outcomes, along with no new safety signals. ARIA rates were low after six months and were not associated with long-term progression, according to the report.

The donanemab and lecanemab results do not show that nightly scent exposure works, or that Alzheimer’s begins in the nasal cavity.

What to Do Now

  1. Discuss a noticeable decline in smell with a clinician, especially if it appears suddenly or changes over time.
  2. Ask about olfactory testing and possible non-Alzheimer’s causes of smell loss, including chronic sinus inflammation.
  3. Use saline rinses after dusty exposure, as suggested in the source material, and consider filtering bedroom air with a true HEPA purifier.
  4. Ask a qualified clinician about smell loss before changing your routine.
  5. Discuss cognitive changes or possible treatment options with a qualified clinician rather than relying on smell loss, nasal research or the small scent trial for a diagnosis.

FAQ

Can a Nasal Biopsy Diagnose Alzheimer’s Disease?

The olfactory epithelium may offer a readily accessible site to monitor the neuroinflammatory processes that are characteristic of Alzheimer’s disease.

This article reports on publicly available information from the sources listed below. We have no reason to believe it is inaccurate, but we have not independently verified every claim, and details may change as the story develops.

Sources

My Account

Sign in to see your orders and your wishlist.

New to SaltyFuelShop? Create an Account
Select the fields to be shown. Others will be hidden. Drag and drop to rearrange the order.
  • Image
  • SKU
  • Rating
  • Price
  • Stock
  • Availability
  • Add to cart
  • Description
  • Content
  • Weight
  • Dimensions
  • Additional information
Click outside to hide the comparison bar
Compare
shopping cart